AtriCure, Inc.
ATRCAtriCure, Inc. (ATRC) is a medical device company that specializes in developing and commercializing advanced medical technologies for the treatment of atrial fibrillation and other cardiac arrhythmias. Founded in 2001, the company focuses on minimally invasive surgical ablation systems and devices that improve patient outcomes by restoring normal heart rhythm. Its products are used by electrophysiologists and cardiac surgeons worldwide.
Company News
AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares valued at $377,000, representing a significant portion of his holdings. Despite the sale, the company shows potential with 16% year-over-year sales growth and improving financial metrics.
Questex's Fierce Healthcare announces the finalists of the second annual Fierce DEI Awards, which celebrate outstanding achievements in Diversity, Equity, and Inclusion within the healthcare industry. The finalists include organizations, initiatives, and individuals recognized for their contributions to creating a more equitable and inclusive hea...
AtriCure, a medical device company, has received approval from China's National Medical Products Administration to market its AtriClip Left Atrial Appendage Exclusion System in China. This is a key development in the company's global expansion strategy, as China represents a significant market opportunity.
In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Beari...
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
